Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083
Maria Babak shared a post by The Babak Lab on LinkedIn:
“Absolutely thrilled to see this groundbreaking study highlighted! The ability to reprogram tumor-associated macrophages using JHU083 to boost the immune response against myeloid-rich prostate and bladder cancers is exceptionally revolutionary.
Don’t miss out on understanding how this could shape the future of oncology! Read more in the study review by The Babak Lab.”
Quoting The Babak Lab’s post:
“Scientific Wednesday: Updates on Cancer Therapy: Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083
Exciting advancements in cancer research!
A recent study ‘Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers’ by Dr. Monali Praharaj and team reveals the potential of the glutamine antagonist JHU083 in reprogramming tumor-associated macrophages (TAMs) to fight myeloid-rich prostate and bladder cancers.
Key Findings:
- Tumor Growth Inhibition – JHU083 reprograms TAMs to increase tumor cell phagocytosis and reduce proangiogenic capacities.
- Enhanced Immune Response – Promotes proinflammatory signaling and immune-proliferative pathways.
- Metabolic Disruption – Causes global shutdown of glutamine-utilizing pathways, leading to tumor cell apoptosis.
- Therapeutic Potential – Offers a promising approach for treating immunosuppressive TAM-rich tumors.
This research underscores the importance of targeting TAM metabolism to boost antitumor immunity and improve cancer immunotherapy outcomes. A promising step forward in the fight against cancer!
Read more here.”
Source: Maria (Masha) Babak/LinkedIn and The Babak Lab/LinkedIn
Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023